Copyright
©The Author(s) 2024.
World J Gastrointest Surg. Jun 27, 2024; 16(6): 1742-1748
Published online Jun 27, 2024. doi: 10.4240/wjgs.v16.i6.1742
Published online Jun 27, 2024. doi: 10.4240/wjgs.v16.i6.1742
Table 3 Comparison of the immune level of the two groups of patients (mean ± SD)
| Group | CD4+ (%) | CD3+ (%) | CD4+/CD8+ (%) | |||
| Before therapy | After treatment | Before therapy | After treatment | Before therapy | After treatment | |
| Control group (50) | 32.78 ± 8.32 | 41.34 ± 10.25 | 52.51 ± 10.32 | 62.78 ± 10.32 | 0.94 ± 0.25 | 1.67 ± 0.12 |
| Therapy group (50) | 32.62 ± 8.66 | 48.26 ± 10.64 | 51.05 ± 10.11 | 73.62 ± 10.66 | 0.96 ± 0.24 | 2.49 ± 0.37 |
| t | 0.094 | -3.312 | 0.715 | -5.166 | -0.408 | -14.907 |
| P value | 0.925 | 0.000 | 0.477 | 0.000 | 0.684 | 0.000 |
- Citation: Fang XQ, Gan T, Wang LM. Clinical effect of spleen aminopeptide on improving liver function damage and immune function in children with infant hepatitis syndrome. World J Gastrointest Surg 2024; 16(6): 1742-1748
- URL: https://www.wjgnet.com/1948-9366/full/v16/i6/1742.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v16.i6.1742